Full Text
Full text is available in PDF
Hepatitis Monthly
Official Journal of Research Center for Gastroenterology and Liver Diseases
Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C
Author(s):
Mohammad Reza Zali1,*, 
Hamid Mohaghegh Shalmani2, Mohsen Norouzinia2, Amir Hooshang MohammadAlizadeh2, Azita Nowroozi2, Negar Behrouz21Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences & Study Group of Interferon in Iran (SG.IFN.IR), [email protected], Tehran, IR.Iran
2Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, IR.Iran
How to Cite:Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C. Hepat Mon. 2004;4(7):. doi:
Abstract
Copyright
© 2004, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
30
Sep
2004
The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial
Nasser Ebrahimi Daryani,
Babak Haghpanah,
Ali Reza Sayyah,
Ali Asad Hashtroudi,
Mohammad Bashashati,
Parisa Poursamimi
,et al.Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7):. doi:
30
Sep
2004
Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian
Seyed Moayed Alavian,
Behzad Hajarizadeh,
Bashir Hajibeigi,
Taher Doroudi,
Amir Kambiz Hamadanizadeh,
Koroush Abar
Alavian S, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadanizadeh A, et al. Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian. Hepat Mon. 2004;4(7):. doi:
1
Jan
2015
Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
Heidar Sharafi,
Seyed Moayed Alavian,
Maryam Keshvari
Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. Hepat Mon. 2015;15(1):e24955. doi: https://doi.org/10.5812/hepatmon.24955
1
Jan
2006
Preliminary Report of Interferon ?2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study
SM Alavian,
A Kabir,
B Hajarizadeh,
M Nayebpour,
T Dorodi,
FE Baralle
Alavian S, Kabir A, Hajarizadeh B, Nayebpour M, Dorodi T, et al. Preliminary Report of Interferon ?2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study. Shiraz E-Med J. 2006;7(1):20390. doi:
14
Dec
2013
Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
Zaigham Abbas,
Ghiasun Nabi Tayyab,
Mustafa Qureshi,
Mohammad Sadik Memon,
Amna Subhan,
Tanzila Shakir
,et al.Abbas Z, Tayyab GN, Qureshi M, Memon MS, Subhan A, et al. Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin. Hepat Mon. 2013;13(12):e14146. doi: https://doi.org/10.5812/hepatmon.14146
Comments
Number of Comments:0Cited by
- Scopus by DOI: 0
Last Update: 2 weeks ago
- Scopus by Title: 0
Last Update: 2 weeks ago
- Scopus by Title (Ref): 2
Last Update: 2 weeks ago
- CrossRef: 0
Last Update: 4 days ago
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC
Search Relations
Author(s):
Related Articles